Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

CSBR Insider Trading

CHAMPIONS ONCOLOGY, INC. | Biological Products, (No Diagnostic Substances)

Comprehensive Trading Performance Summary

The investment history of corporate insiders at CHAMPIONS ONCOLOGY, INC. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2024-01-16 19:45 2024-01-12 Mendelson Daniel Newman Director BUY $6.50 1,000 $6,500 198,625 +0.5%
2024-01-12 20:47 2024-01-11 Mendelson Daniel Newman Director BUY $6.27 2,000 $12,540 197,625 +1.0%
2024-01-11 18:57 2024-01-10 Mendelson Daniel Newman Director BUY $6.31 2,944 $18,577 195,625 +1.5%
2024-01-10 16:57 2024-01-09 Mendelson Daniel Newman Director BUY $6.25 3,000 $18,750 192,681 +1.6%
2024-01-09 17:08 2024-01-08 Mendelson Daniel Newman Director BUY $6.15 1,000 $6,150 189,681 +0.5%
2024-01-08 23:11 2024-01-05 Mendelson Daniel Newman Director BUY $6.09 2,000 $12,180 188,681 +1.1%
2024-01-08 22:54 2024-01-04 Mendelson Daniel Newman Director BUY $6.12 3,000 $18,360 186,681 +1.6%
2024-01-04 21:37 2024-01-03 Mendelson Daniel Newman Director BUY $5.83 500 $2,915 183,681 +0.3%
2023-12-26 19:48 2023-12-21 Mendelson Daniel Newman Director BUY $4.92 2,500 $12,300 183,181 +1.4%
2023-12-21 22:31 2023-12-20 Mendelson Daniel Newman Director BUY $4.82 2,100 $10,122 180,681 +1.2%
2023-12-20 17:48 2023-12-19 Mendelson Daniel Newman Director BUY $4.75 5,000 $23,750 178,581 +2.9%
2023-10-16 16:53 2023-09-29 Mendelson Daniel Newman Director BUY $6.16 4,000 $24,640 173,581 +2.4%
2023-10-16 16:52 2023-09-28 Mendelson Daniel Newman Director BUY $6.22 5,000 $31,100 169,581 +3.0%
2023-10-16 16:51 2023-09-27 Mendelson Daniel Newman Director BUY $5.95 1,500 $8,925 164,581 +0.9%
2023-10-13 19:48 2023-10-11 Mendelson Daniel Newman Director BUY $6.40 5,000 $32,000 163,081 +3.2%
2023-10-11 16:45 2023-10-10 Mendelson Daniel Newman Director BUY $6.41 1,100 $7,051 158,081 +0.7%
2023-10-10 17:02 2023-10-06 Mendelson Daniel Newman Director BUY $6.48 1,530 $9,914 156,981 +1.0%
2023-10-06 14:10 2023-10-05 Mendelson Daniel Newman Director BUY $6.47 2,000 $12,940 155,451 +1.3%
2023-10-05 00:31 2023-10-03 Mendelson Daniel Newman Director BUY $6.30 2,500 $15,750 148,451 +1.7%
2023-10-05 00:30 2023-10-04 Mendelson Daniel Newman Director BUY $6.40 5,000 $32,000 153,451 +3.4%
2023-09-27 16:56 2023-09-26 Mendelson Daniel Newman Director BUY $5.65 5,000 $28,250 145,951 +3.5%
2023-09-25 22:00 2023-09-19 Mendelson Daniel Newman Director BUY $5.28 5,000 $26,400 128,121 +4.1%
2023-09-25 21:59 2023-09-20 Mendelson Daniel Newman Director BUY $5.51 4,018 $22,139 132,139 +3.1%
2023-09-25 21:59 2023-09-21 Mendelson Daniel Newman Director BUY $5.51 5,000 $27,550 137,139 +3.8%
2023-09-25 21:59 2023-09-22 Mendelson Daniel Newman Director BUY $5.50 3,812 $20,966 140,951 +2.8%
2023-03-21 19:30 2023-03-17 Morris Ronnie Director, Officer - CEO BUY $4.04 12,382 $49,969 858,878 +1.5%
2020-12-17 17:29 2020-12-16 Breitfeld Philip P. Director SELL $11.35 31,443 $356,976 0 -100.0%
2020-03-30 23:56 2020-03-26 Mendelson Daniel Newman Director BUY $5.91 1,220 $7,213 58,746 +2.1%
2020-03-26 21:52 2020-03-24 Morris Ronnie Director, Officer - CEO SELL $5.25 75 $394 837,168 0.0%
2020-03-26 22:00 2020-03-24 Mendelson Daniel Newman Director BUY $5.50 26 $143 57,526 +0.0%
2020-03-24 16:54 2020-03-20 Morris Ronnie Director, Officer - CEO BUY $4.75 75 $356 837,243 +0.0%
2020-03-10 23:45 2020-03-06 New Enterprise Associates 14, L.P. 10% owner SELL $6.99 708,155 $4,950,003 1,713,720 -29.2%
2018-12-20 23:18 2018-12-19 Morris Ronnie Director, Officer - CEO BUY $7.44 20,000 $148,800 833,001 +2.5%
2018-11-09 01:02 2018-11-06 Mendelson Daniel Newman Director SELL $13.75 5,000 $68,750 57,500 -8.0%
2018-10-05 17:30 2018-09-20 Mendelson Daniel Newman Director SELL $13.02 8,333 $108,496 62,500 -11.8%
2018-10-03 17:22 2018-10-01 ACKERMAN JOEL Director SELL $17.02 22,535 $383,546 1,021,731 -2.2%
2018-03-29 00:26 2018-03-26 Morris Ronnie Director, Officer - CEO BUY $3.59 4,535 $16,298 1,116,582 +0.4%
2018-03-26 23:05 2018-03-22 Morris Ronnie Director, Officer - CEO BUY $3.50 700 $2,447 1,112,047 +0.1%
2016-10-24 21:05 2016-10-21 Morris Ronnie Director, Officer - President BUY $1.66 30,000 $49,899 1,111,347 +2.8%
2016-10-20 23:35 2016-10-19 Morris Ronnie Director, Officer - President BUY $1.70 10,000 $17,000 1,081,347 +0.9%
2016-10-20 18:13 2016-10-18 ACKERMAN JOEL Director, Officer - Chief Executive Officer BUY $1.70 2,000 $3,393 1,044,266 +0.2%
2016-10-17 16:54 2016-10-14 Morris Ronnie Director, Officer - President BUY $1.66 10,305 $17,106 1,071,347 +1.0%
2016-10-14 20:09 2016-10-13 Morris Ronnie Director, Officer - President BUY $1.67 29,695 $49,493 1,061,042 +2.9%
2016-10-14 23:40 2016-10-13 ACKERMAN JOEL Director, Officer - Chief Executive Officer BUY $1.67 7,300 $12,206 1,042,266 +0.7%
2016-10-11 17:38 2016-10-10 Morris Ronnie Director, Officer - President BUY $1.66 9,537 $15,831 1,031,347 +0.9%
2016-10-07 21:18 2016-10-06 ACKERMAN JOEL Director, Officer - Chief Executive Officer BUY $1.63 8,202 $13,369 1,034,966 +0.8%
2016-09-26 23:24 2016-09-23 ACKERMAN JOEL Director, Officer - Chief Executive Officer BUY $1.65 33 $54 1,026,764 +0.0%
2016-09-21 21:27 2016-09-20 Morris Ronnie Director, Officer - President BUY $1.58 3,000 $4,740 1,021,810 +0.3%
2016-09-21 21:26 2016-09-20 ACKERMAN JOEL Director, Officer - Chief Executive Officer BUY $1.66 5,000 $8,324 1,026,731 +0.5%
2015-03-17 23:20 2015-03-11 Morris Ronnie Director, Officer - President BUY $0.00 2,710,526 $0 3,572,174 +314.6%
SHOW ENTRIES

How to Interpret $CSBR Trades

Not every insider transaction in CHAMPIONS ONCOLOGY, INC. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CSBR shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for CSBR

Insider activity data for CHAMPIONS ONCOLOGY, INC. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CSBR, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.